Zambon Presents Results from the Two Phase 3 PROMIS Studies of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis at World Bronchiectasis Conference 2023
MILAN, Italy and Boston, MA, May 23, 2023 — Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced that the Company presented results from a study evaluating the humanistic burden of bronchiolitis obliterans syndrome (BOS) after lung transplant (LTx) or allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the American Thoracic Society (ATS) 2023 Annual Meeting being held May 19 - 24, 2023 in Washington, D.C.
MILAN, Italy and Boston, MA, May 8, 2023 — Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the presentation of data from a health economic outcomes study characterizing the lifetime burden of illness for U.S. patients diagnosed with bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) or lung transplantation at the 2023 Virtual International Society for the Pharmacoeconomic and Outcomes Research (ISPOR) conference being held from May 7-10 in Boston, MA.
Milan, Italy and Boston, MA, May 1, 2023 —Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, announced today that the Company has completed enrollment in its two pivotal Phase 3 studies. The trials are designed to evaluate the safety and efficacy of Liposomal Cyclosporine A for Inhalation (L-CsA-i) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation.
Zambon and IMA Active: paving the way towards process optimisation
MILAN and BOSTON, Oct. 14, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, announced today that the Company will present findings examining how Chronic Lung Allograft Dysfunction (CLAD) is the leading cause of re-transplantation and associated with high healthcare costs during a rapid oral session at the American College of Chest Physicians® (CHEST) 2022 Annual Meeting being held October 16 – 19, 2022 in Nashville, TN.
Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
BOSTON, April 26, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, is presenting two posters at the International Society for Heart and Lung Transplantation (ISHLT) Annual 2022 Meeting taking place April 27–30 in Boston, MA.
In recent years, with the change of consumers' concept and the increasing demand for beauty, the medical cosmetology market has been booming, among which, Sodium Hyaluronate (as known as Hyaluronic Acid) and botox are the best-selling medical cosmetology items. Sodium Hyaluronate is mainly used in field of non-surgical injection therapy.